ArticleParkinsonism & related disorders2025
Can we detect cognitive "super-agers" in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease.
Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionSuperagers are older individuals who resist age-related cognitive decline and who perform just as well or better than younger people in cognitive tasks. In healthy aging studies, superagers not only experience positive cognitive outcomes (e.g. lower risk of future mild cognitive impairment), but may also experience fewer depressive and anxiety symptoms as they age. We seek to identify superagers in Parkinson's disease (PD) and potential outcomes associated with superager status.
methodsData was gathered from the Parkinson's Progression Markers Initiative (PPMI). 689 individuals newly diagnosed with PD were assessed annually for up to 10 years. Participants were classified into three groups: superagers, cognitively normal, and PD mild cognitive impairment (PD-MCI). Multilevel models examined longitudinal group differences in global cognition, depression, anxiety, and motor severity.
resultsA significant main effect of group revealed that superagers performed better than the PD-MCI and cognitively normal groups in global cognition. There were significant group by time interactions, revealing the superagers group was on a more favorable longitudinal trajectory relative to other two groups. Superagers also reported less severe depressive and anxiety symptoms compared to the PD-MCI and the cognitively normal groups. Superagers had a more favorable trajectory of motor symptom severity relative to the cognitively normal and PD-MCI groups.
conclusionSuperagers with PD may be detected with neuropsychological testing and appear to resist the effects of neurodegeneration in Parkinson's disease. Cognitive studies and trials may benefit from incorporating the concept of superagers, as opposed to a single homogenous cognitively normal group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.